Asia stocks rise: Japan surges on Takaichi bets, China buoyed by positive GDP
Investing.com - Jefferies raised its price target on Cellectis (NASDAQ:CLLS) to $6.00 from $5.00 while maintaining a Buy rating following the company’s R&D day in New York City.
The firm expressed greater appreciation for Cellectis’ CD22 alloCAR-T therapy lasme-cel after reviewing the full Phase 1 data disclosed at the event.
Lasme-cel demonstrated a 100% overall response rate (ORR) and 56% complete response/complete response with incomplete hematologic recovery (CR/CRi) in the pivotal trial population at the recommended Phase 2 dose (RP2D) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
Jefferies noted that treatment options are limited in late-line r/r B-ALL and sees a clear regulatory path for the therapy in both the US and EU with a newly announced single-arm pivotal design.
Cellectis plans to present additional data at the upcoming American Society of Hematology (ASH) meeting and intends to start the pivotal study in the fourth quarter.
In other recent news, Barclays has raised its price target for Cellectis to $8.00, up from the previous target of $4.00. This adjustment follows the company’s recent R&D day, where significant progress was showcased. Cellectis’ lasme-cel (UCART22) therapy has shown promising results, particularly in treating relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). The therapy demonstrated complete response rates of 42% at the pivotal dose and 56% in the target population. Barclays has maintained an Overweight rating on Cellectis, reflecting optimism about the company’s advancements. These developments indicate the potential effectiveness of Cellectis’ cancer therapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.